KR20180047602A - FOOD COMPOSITION CONTAINING HYDROLYSATE DERIVED FROM Hippocampus abdominalis AND EXTRACT OF RED GINSENG FOR RELIEVING FATIGUE - Google Patents
FOOD COMPOSITION CONTAINING HYDROLYSATE DERIVED FROM Hippocampus abdominalis AND EXTRACT OF RED GINSENG FOR RELIEVING FATIGUE Download PDFInfo
- Publication number
- KR20180047602A KR20180047602A KR1020160143978A KR20160143978A KR20180047602A KR 20180047602 A KR20180047602 A KR 20180047602A KR 1020160143978 A KR1020160143978 A KR 1020160143978A KR 20160143978 A KR20160143978 A KR 20160143978A KR 20180047602 A KR20180047602 A KR 20180047602A
- Authority
- KR
- South Korea
- Prior art keywords
- red ginseng
- hippocampus
- hydrolyzate
- fatigue
- ginseng extract
- Prior art date
Links
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 60
- 239000000284 extract Substances 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 241001559553 Hippocampus abdominalis Species 0.000 title claims abstract description 7
- 235000013305 food Nutrition 0.000 title claims description 8
- 239000000413 hydrolysate Substances 0.000 title abstract 3
- BHCBLTRDEYPMFZ-UHFFFAOYSA-N 5-acetamido-1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide Chemical compound CC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I BHCBLTRDEYPMFZ-UHFFFAOYSA-N 0.000 title 1
- 235000013376 functional food Nutrition 0.000 claims abstract description 11
- 230000036541 health Effects 0.000 claims abstract description 11
- 235000013402 health food Nutrition 0.000 claims abstract description 3
- 210000001320 hippocampus Anatomy 0.000 claims description 37
- 230000000971 hippocampal effect Effects 0.000 claims description 15
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 2
- 102000005158 Subtilisins Human genes 0.000 abstract description 29
- 108010056079 Subtilisins Proteins 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 19
- 102000004190 Enzymes Human genes 0.000 abstract description 9
- 108090000790 Enzymes Proteins 0.000 abstract description 9
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 4
- 238000009825 accumulation Methods 0.000 abstract description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 description 35
- 241000252212 Danio rerio Species 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 13
- 210000003205 muscle Anatomy 0.000 description 13
- 230000004663 cell proliferation Effects 0.000 description 9
- 229920002527 Glycogen Polymers 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 229940096919 glycogen Drugs 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 6
- 229940116871 l-lactate Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000003098 myoblast Anatomy 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241001559542 Hippocampus hippocampus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229960002666 1-octacosanol Drugs 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 206010027304 Menopausal symptoms Diseases 0.000 description 3
- 201000001880 Sexual dysfunction Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000012888 bovine serum Substances 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 231100000872 sexual dysfunction Toxicity 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 240000003291 Armoracia rusticana Species 0.000 description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 244000132059 Carica parviflora Species 0.000 description 2
- 235000014653 Carica parviflora Nutrition 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- -1 antiarthritic Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000004276 hyalin Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 1
- 241001105098 Angelica keiskei Species 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 241001559544 Hippocampus guttulatus Species 0.000 description 1
- 241001478424 Hippocampus kuda Species 0.000 description 1
- 101000761717 Hydrophis lapemoides Short neurotoxin 1 Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 101000800747 Ophiophagus hannah Long neurotoxin 1 Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241001247203 Syngnathidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 208000027499 body ache Diseases 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 108010007119 flavourzyme Proteins 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000003898 horticulture Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108010009355 microbial metalloproteinases Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
- A23V2250/2042—Marine animal, fish extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/55—Peptide, protein hydrolysate
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 가수분해물을 이용하여 제조한 해마 가수분해물과 홍삼 추출물을 배합한 혼합물을 함유하는 건강 기능성 식품 조성물로 보다 상세하게는, Alcalase 가수분해 효소를 이용하여 해마 가수분해물을 제조하고, 해마 사용을 식품에서 50% 이하로 사용해야 하는 국내 실정에 맞추어 해마 가수분해물과 홍삼 추출물을 배합함으로써 피로개선의 효과가 있는 해마 가수분해물과 홍삼 추출물의 혼합물을 함유하는 피로개선용 건강 기능성 식품 조성물에 관한 것이다.
The present invention relates to a health functional food composition containing a mixture of a hippocampus hydrolyzate and a red ginseng extract prepared using a hydrolyzate, more particularly, to a horseradish hydrolyzate prepared by using an Alcalase hydrolyzing enzyme, The present invention relates to a health functional food composition for improving fatigue containing a mixture of hippocampal hydrolyzate and red ginseng extract having an effect of improving fatigue by mixing hippocampal hydrolyzate and red ginseng extract in accordance with the domestic situation which should be used at 50% or less in food.
해마는 실고기과에 속하는 경골어류로서 52속 215종 중에 해마속 어류 32종이 분류되며 우리나라에는 해마, 가시해마, 복해마, 산호해마, 그리고 점해마 등의 5종이 서식하고 있다. The hippocampus is a tibia fish belonging to the spindle group, and among the 52 genera 215 species, 32 species of hippocampus are classified. In Korea, there are five species of hippocampus, hippocampus, coral hippocampus, and coral hippocampus.
유럽과 북미에서는 관상용과 건조시켜 기념품이나 골동품 등으로 상품화한 데 반해, 해마는 천식, 간 기능 장애, 성기능 향상 그리고 일반적인 통증에 효능이 있는 것으로 알려져, 중국을 비롯한 동남아시아에서는 약제로서 사용되어져 왔다.In Europe and North America, horticulture has been used as a medicine in Southeast Asia, including China, because it is said to be effective for asthma, liver dysfunction, sexual dysfunction and general pain, while ornamental use and drying to commercialize it as a souvenir or antique.
해마의 주요 구성 성분들은 스테로이드, 미네랄, 아미노산 펩타이드 지방산으로 알려져 있고, 해마의 약제로서의 효능에 주력하여 종래의 연구들에서는 항암, 항노화, 항혈전, 항관절염, 항산화, 발기부전 완화, 신경 보호 작용과 같은 효과가 밝혀졌다. The major constituents of the hippocampus are known as steroids, minerals and amino acid peptide fatty acids, and they focus on the efficacy of the hippocampus as drugs. Conventional studies have shown that anti-cancer, anti-aging, antithrombotic, antiarthritic, antioxidant, erectile dysfunction, And the effect was revealed.
빅벨리해마(Hippocampus abdominalis)는 큰가시고기목(Syngnathifromes), 실고기과(Syngnathidae) 에 속하며 온대와 열대해역에 서식하고 해마들 중에서도 크기가 가장 크고 아름다운 체색과 체형을 지니고 있어 관상가치가 높아 국제 해수 관상생물 시장에서도 인기가 많다. Hippocampus abdominalis belongs to Syngnathifromes and Syngnathidae. It lives in temperate and tropical waters. It has the largest size among hippocampus and has beautiful body color and body shape, It is also popular in the coronary market.
이미 뉴질랜드, 호주, 중국에서 해마양식이 시도되었고, 최근 제주에서는 식용으로 지정된 빅벨리해마의 완전 양식이 성공하였다. 하지만 이전에 많은 생리활성 연구가 진행된 북해마 (Hippocampus kuda Bleeker), 갈귀해마(Hippocampus guttu- latus), Short-snouted seahorse (Hippocampus hippocampus) 종 등에 비해 빅벨리해마는 생리활성 연구가 많이 부족한 상황이다. Hippocampus farming has already been tried in New Zealand, Australia and China, and in recent years, full breeding of the Big Veli hippocampus designated as edible has been successful in Jeju. However, the research on physiological activity of the Bigbellie hippocampus has been lacking compared with that of the Hippocampus kuda Bleeker, Hippocampus guttu- latus and Short-snouted seahorse (Hippocampus hippocampus) species,
본 발명의 출원인에 의해 빅벨리해마의 소화효소 2종(trypsin, pepsin)과 식품용 가수분해 효소 5종(neutrase, protamex, alcalase, koji- zyme, flavourzyme)을 이용한 빅벨리해마 가수분해물들의 제조와 가수분해물 유래의 각 분자량별 분획물을 이용해 염증을 유발하고 세포 내 조직을 손상시키며, 노화와 암, 당뇨, 뇌졸증, 동맥경화, 심혈관 질환, 빈혈, 위궤양, 치매 등의 질병을 야기하는 원인으로 알려져 있는 자유 라디칼에 대한 소거능을 확인함으로써 해마의 항산화 활성에 관한 연구는 진행된 바가 있으나, 후술할 본 발명의 빅벨리해마 가수분해물의 항피로 효능에 대한 연구는 진행되어진 적이 없다. The inventors of the present invention have found that the production of Bigvalley hippocampal hydrolysates using two digestive enzymes (trypsin, pepsin) and five food hydrolytic enzymes (neutrase, protamex, alcalase, koji-zyme and flavourzyme) It is known to cause inflammation and damage intracellular tissues by using fractions of respective molecular weights derived from hydrolyzate and causes diseases such as aging and cancer, diabetes, stroke, arteriosclerosis, cardiovascular disease, anemia, gastric ulcer and dementia Studies on the antioxidative activity of the hippocampus by confirming the scavenging ability against the free radicals have been conducted, but research on the anti-fatigue efficacy of the hydrolyzate of the hippocampus of the present invention has not been conducted.
피로는 육체적 피로와 정신적 피로로 나눌 수 있고, 증상은 무기력한 상태에서부터 졸림, 근육통, 오한을 동반하는 몸살 등 다양하게 나타나며, 피로가 거듭 되풀이되면 만성피로 증후군을 일으킬 수 있다. 바쁜 생활 속의 현대인들은 활동량의 부족, 정신적인 스트레스, 게으른 습관 및 비만 등으로 인해 피로가 쉽게 나타나, 질병 없이 건강을 유지하고자 하는 관심과 욕구는 점점 높아지고 있다. Fatigue can be divided into physical fatigue and mental fatigue. Symptoms can vary from helpless to drowsiness, muscle aches, and body aches accompanied by chills. Repeated fatigue can cause chronic fatigue syndrome. Modern people in a busy life are becoming tired easily due to lack of activity, mental stress, lazy habits and obesity, and interest and desire to maintain health without disease are getting higher and higher.
일반적으로 피로는 운동 시 세포들의 적절한 에너지 공급을 위하여 산소요구량이 급격히 증가하게 되는데 이때 세포들의 대사가 산소요구량을 충족시키지 못하면 세포는 일시적인 무산소 대사에 의한 에너지 공급 상태가 되어 lactate의 생성과 축적으로 인하여 피로를 유발하게 된다. 따라서 많은 사람들이 피로회복과 건강증진 및 질병예방을 위한 영양물질을 보충하고자 건강 기능성 식품의 섭취를 선호하고 있는 실정이다. In general, fatigue causes a rapid increase in oxygen demand for proper energy supply of cells during exercise. If the metabolism of the cells does not satisfy the oxygen demand, the cells become temporarily supplied with energy by oxygen-free metabolism, Causing fatigue. Thus, many people prefer to take health-functional foods to supplement their nutritional support for fatigue, health promotion and disease prevention.
본 발명은 국내에서 해마의 식품용 사용을 50% 미만으로 제한한 조건을 만족하기 위하여 이미 항피로 효능으로 건강기능성 인정을 받은 홍삼과 배합하여 상승효과가 나타나는 가장 우수한 해마 가수분해물의 배합비율을 확인함으로서, 빅벨리해마 가수분해물과 홍삼 추출물을 포함하는 피로개선용 조성물을 제공하고자 한다.
In order to satisfy the condition that the use of hippocampus for food is limited to less than 50%, the present invention relates to a method for determining the compounding ratio of the best hippocampal hydrolyzate having a synergistic effect by combining with red ginseng which has already been recognized as having an anti- Thus, it is intended to provide a composition for improving fatigue including hydrolysates of Bigbell horse seaweed and extracts of red ginseng.
본 발명은 식품에 있어 해마사용을 50% 이하로 한정해야 하는 국내 실정에 맞추어 Alcalase 가수분해 효소를 이용하여 제조한 가수분해물과 종래의 피로개선의 효과가 알려져 있는 홍삼 추출물을 배합시킴으로써, 50% 이하의 포함량을 만족시키면서 최대의 피로개선의 효과가 있는 해마 가수분해물과 홍삼 추출물의 혼합물을 함유하는 피로개선용 건강 기능성 식품 조성물을 제공하고자 한다.
According to the present invention, hyaluronic acid hydrolyzate prepared by using Alcalase hydrolysis enzyme is mixed with red ginseng extract, which is known for its fatigue improvement effect, to be 50% or less And a mixture of the hippocampal hydrolyzate and the red ginseng extract, which has the maximum fatigue improving effect while satisfying the content of the hyaluronic acid hydrolyzate and the red ginseng extract.
상기 문제를 해결하기 위한 수단으로서 본 발명은 해마 가수분해물과 홍삼 추출물의 혼합물을 함유하는 피로개선용 건강 기능성 식품 조성물을 제공한다. 상기 해마는 Hippocampus abdominalis로, 해마 가수분해물은 해마 건조시료에 Alcalase 단백질 가수분해 효소로 처리하여 얻어지며, 해마 가수분해물과 홍삼 추출물은 1:1.5-4 중량비로 배합되며, 혼합물의 농도는 200 내지 500 ㎍/ml이다.As a means for solving the above problem, the present invention provides a health functional food composition for improving fatigue containing a mixture of hippocampal hydrolyzate and red ginseng extract. The hippocampus is Hippocampus abdominalis , the hippocampus hydrolyzate is obtained by treating the hippocampal dry sample with Alcalase protein hydrolyzing enzyme, the hippocampus hydrolyzate and the red ginseng extract are mixed at a weight ratio of 1: 1.5-4, and the concentration of the mixture is 200 to 500 ㎍ / ml .
또한, 상기 조성물을 함유하는 해마 가수분해물과 홍삼 추출물의 혼합물을 함유하는 피로개선용 건강식품을 제공한다.
Also provided is a health food for improving fatigue containing a mixture of hippocampus hydrolyzate and red ginseng extract containing the composition.
후술된 실시예에 기재된 바와 같이, 해마 가수분해물과 홍삼 추출물의 혼합물을 함유하는 피로개선용 건강 기능성 식품 조성물을 마우스 유래 근아세포인 C2C12 세포주에 처리하여, 그 결과로서 세포증식 효능을 확인하였고, 해마 가수분해물과 홍삼 추출물이 1:1.5-4 중량비로 배합되었을 때 홍삼 100% 추출물보다 피로개선 활성효과가 있었음을 확인하였다.As described in the following examples, a health functional food composition for fatigue improvement containing a mixture of hippocampal hydrolyzate and red ginseng extract was treated with a mouse-derived myoblast C2C12 cell line to confirm cell proliferation efficacy, When the hydrolyzate and red ginseng extract were combined at a weight ratio of 1: 1.5-4, it was confirmed that the activity of improving fatigue was higher than that of
In vivo 모델로 Zebrafish를 사용하여 근육내 glycogen 및 ATP 함량과 lactate 함량을 측정한 결과, 해마 가수분해물과 홍삼 추출물이 1:1.5-4 중량비로 배합되었을 때 glycogen 함량이 많았고, 피로 유발 물질인 L-Lactate 함량이 현저히 적게 생성되었으며, ATP 함량이 높아 피로개선에 효능이 있음을 확인하였다.In the in vivo model, glycogen and ATP content and lactate content were measured by using Zebrafish. When the hippocampus hydrolyzate and red ginseng extract were combined at a weight ratio of 1: 1.5-4, the content of glycogen was high and the fatigue inducing substance, L- Lactate content was remarkably low and ATP content was high.
상기 실시예들의 결과를 통해서 본 발명의 해마 가수분해물과 홍삼 추출물은 1:1.5-4 중량비로 배합되고 200 내지 500 ㎍/ml 농도의 혼합물을 함유하는 본 발명의 조성물은 피로개선의 효과가 있는 것으로 사료된다.
The results of the above Examples show that the composition of the present invention containing the mixture of hippocampus hydrolyzate and red ginseng extract at a weight ratio of 1: 1.5-4 and containing a concentration of 200 to 500 / / ml has the effect of improving fatigue .
도 1은 해마 Alcalase 가수분해물과 홍삼 추출물의 배합비율 농도별 세포독성 평가 결과를 나타낸다.
도 2는 해마 Alcalase 가수분해물과 홍삼 추출물의 배합비율 농도별 세포증식 효능 결과를 나타낸다.
도 3은 해마 Alcalase 가수분해물과 홍삼 추출물의 배합비율 농도별 피로개선 효능 결과를 나타낸다.
도 4는 In vivo 모델에서의 피로개선 활성측정을 위한 운동 수조를 나타낸다.
도 5는 In vivo 모델인 Zebrafish의 EthoVision®system을 이용한 유영분석 결과를 나타낸다.
도 6은 In vivo 모델인 zebrafish 근육 내 glycogen 함량을 나타낸다.
도 7은 In vivo 모델인 zebrafish 근육내 L-Lactate 함량을 나타낸다.
도 8은 In vivo 모델인 zebrafish 근육내 ATP 함량을 나타낸다.FIG. 1 shows the cytotoxicity evaluation results of the concentration ratio of Alcalase hydrolyzate and red ginseng extract in horses.
Fig. 2 shows the cell proliferation efficacy results by the concentration ratio of Alcalase hydrolyzate and red ginseng extract of hippocampus.
FIG. 3 shows fatigue-improving efficacy results by the concentration ratio of Alcalase hydrolyzate and red ginseng extract.
Figure 4 shows a running water bath for measuring fatigue improving activity in an in vivo model.
Figure 5 shows the results of a swimming analysis using the EthoVision system of Zebrafish, an in vivo model.
Figure 6 shows the glycogen content in the in vivo model zebrafish muscle.
Fig. 7 shows the content of L-lactate in the in vivo model zebrafish muscle.
Figure 8 shows the ATP content in the zebrafish muscle, an in vivo model.
이하, 본 발명을 구체적인 실시예를 들어 자세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail with reference to specific examples.
1. One. 빅벨리Big Valley 해마 hippocampus 가수분해물과Hydrolyzate and 홍삼추출물이 혼합된 조성물 제조 Preparation of a composition mixed with red ginseng extract
1.1 1.1 빅벨리Big Valley 해마 hippocampus 가수분해물Hydrolyzate 제조 Produce
본 발명 실시예에서 사용한 실험어는 제주 한국해수관상어센터에서 양식 생산되는 빅벨리 해마(Hippocampus abdominalis)를 동결건조 후 분쇄하여 -70℃에 보관하며 사용하였다. The experimental fishes used in the examples of the present invention were the Big-belly hippocampus ( Hippocampus abdominalis ) were lyophilized, pulverized and stored at -70 ° C.
Alcalase 가수분해효소를 사용하여 기질 대 효소비를 100:1로 하였으며, 24 시간동안 가수분해를 실시하였고, 효소반응 정지를 위해 100℃에서 10분간 효소를 불활성화 시킨 후 pH를 7.0으로 조정하였다. 이후 20분간 원심분리를 한 뒤 잔사를 제외한 상층액을 여과지를 사용하여 여과하여 동결건조 후 분말화하여 실험에 사용하였다. Alcalase hydrolysis enzyme was used to adjust the substrate to enzyme ratio to 100: 1. Hydrolysis was performed for 24 hours. The enzyme was inactivated at 100 ° C for 10 minutes to stop the enzyme reaction, and the pH was adjusted to 7.0. After centrifugation for 20 minutes, the supernatant, except for the residue, was filtered through filter paper, lyophilized, and powdered.
또한 본 발명에서 사용되는 홍삼추출물은 시판되는 농축액으로 (주)일화 홍삼농축액을 구입하여 사용하였다. 상기 해마 가수분해물과 홍삼 추출물은 1:1.5-4 중량비로 배합하여 실험을 진행하였다.
In addition, the red ginseng extract used in the present invention was purchased from a commercial concentrated red ginseng concentrate. The hippocampus hydrolyzate and red ginseng extract were mixed at a weight ratio of 1: 1.5-4.
1.2 세포독성 평가 실험1.2 Cytotoxicity assay
마우스 유래 근아세포인 C2C12 세포주를 10% 소혈청(bovine serum)과 L-글루타민을 포함하는 DMEM (Dulbeccos’modified Eagle’medium) 배지를 이용하여 37℃, 5% CO2 배양기에서 배양하였다. The mouse-derived myoblast C2C12 cell line was cultured in DMEM (Dulbeccos'modified Eagle'medium) medium containing 10% bovine serum and L-glutamine at 37 ° C in a 5% CO 2 incubator.
48 well plate에 5×104 cells/ml로 분주한 후, 16 시간이 지난 후 10% 말 혈청이 들어간 DMEM 배지로 바꿔주었다. 샘플은 상기 제조한 해마 Alcalase 가수분해물과 홍삼 추출물의 배합비율(홍삼배합비율 기준으로 20%~80%)과 농도별로 (50, 100, 200, 250, 500 ㎍/ml처리하였고 24시간 동안 배양하였다.여기서 홍삼 배합비율기준이란 예를 들어 홍삼 추출물이 20%이면 해마가수분해 추출물은 80%로 이루어지는 것을 의미한다. The cells were divided into 48 well plates at 5 × 10 4 cells / ml, and after 16 hours, they were changed to DMEM containing 10% horse serum. The samples were treated with the hydrolyzate of Alcalase hydrolyzate and red ginseng extract (20% to 80% based on the mixing ratio of red ginseng) and the concentration (50, 100, 200, 250 and 500 / / ml) For example, the red ginseng extract content of 20% means that the hydrolysis extract of hippocampus consists of 80%.
세포독성 평가를 측정하기 위하여 MTT assay를 실시하였고, 원리는 생존하면서 대사가 왕성한 세포 내 mitochondria의 탈수소효소 작용에 의하여 수용성의 노란색 MTT [3-(4,5-dimethylthiaxol-2-yl)-2,5-diphenyl tetrazolium bromide]를 환원시켜 자주색을 띠는 비 수용성의 formazan을 측정하는 것이다. The MTT assay was performed to measure the cytotoxicity and the principle was that the soluble yellow MTT [3- (4,5-dimethylthiaxol-2-yl) -2, 5-diphenyl tetrazolium bromide] is reduced to measure purple colored water-insoluble formazan.
24시간이 지난 후, MTT 용액 50 μl (2 mg/ml)을 첨가하여 2시간 동안 반응시킨다. 상층액을 완전히 제거하고 dimethylsulfoxide (DMSO)를 가하여 침전물을 완전히 용해시킨 후 540 nm에서 흡광도를 측정하였다. After 24 hours, add 50 μl of MTT solution (2 mg / ml) and allow to react for 2 hours. The supernatant was completely removed and dimethylsulfoxide (DMSO) was added to completely dissolve the precipitate and the absorbance was measured at 540 nm.
도 1은 해마 Alcalase 가수분해물과 홍삼 추출물의 배합비율 농도별 세포독성 평가 결과를 나타낸다. 상기 실험 결과 해마 Alcalase 가수분해물과 홍삼 추출물의 배합비율 농도별 처리 시 세포독성이 없음을 확인할 수 있었다.
FIG. 1 shows the cytotoxicity evaluation results of the concentration ratio of Alcalase hydrolyzate and red ginseng extract in horses. As a result of the experiment, it was confirmed that there was no cytotoxicity at the treatment rate of the hyaluronic acid Alcalase hydrolyzate and red ginseng extract.
2. 해마 2. Seahorse AlcalaseAlcalase 가수분해물과Hydrolyzate and 홍삼 추출물로 이루어진 조성물의 피로개선 Improvement of fatigue of composition composed of red ginseng extract
2.1 세포증식 효능2.1 Cell proliferation efficacy
마우스 유래 근아세포인 C2C12 세포주를 10% 소혈청(bovine serum)과 L-글루타민을 포함하는 DMEM (Dulbeccos’modified Eagle’medium) 배지를 이용하여 37℃, 5% CO2 배양기에서 배양하였다. The mouse-derived myoblast C2C12 cell line was cultured in DMEM (Dulbeccos'modified Eagle'medium) medium containing 10% bovine serum and L-glutamine at 37 ° C in a 5% CO 2 incubator.
48 well plate에 5×104 cells/ml로 분주한 후, 16 시간이 지난 후 10% 말 혈청이 들어간 DMEM 배지로 바꿔주었다. 샘플은 상기 제조한 해마 Alcalase와 홍삼 추출물 배합비율(홍삼배합비율 기준으로 0%, 20%, 40%, 60%, 80%, 100%) 농도별로 (200, 250, 300, 400, 500 ㎍/ml처리하였고 총 4일간 배양하였다. The cells were divided into 48 well plates at 5 × 10 4 cells / ml, and after 16 hours, they were changed to DMEM containing 10% horse serum. 300, 400, 500 ㎍ / ㎖) for each concentration of horseradish Alcalase and red ginseng extract (0%, 20%, 40%, 60%, 80% ml and cultured for a total of 4 days.
4일간 배양하는 동안 2일에 한 번씩 배지를 새로 바꿔주고, 샘플도 다시 처리하였다. 총 4일간 배양 후에 세포증식 효능을 측정하기 위하여 MTT assay를 이용하여 실험하였다. During the 4-day incubation, the medium was replaced once every two days and the samples were again treated. MTT assay was used to measure cell proliferation after 4 days of culture.
도 2는 해마 Alcalase 가수분해물과 홍삼 추출물의 배합비율 농도별 세포증식 효능 결과를 나타낸다. 상기 실험 결과, 해마 Alcalase 가수분해물과 홍삼 추출물의 배합비율이 0%, 20% 일 때 200, 250 ㎍/ml에서 세포증식 효능이 가장 우수하였고, 이와 같은 결과를 통해 해마 Alcalase 가수분해물 자체가 세포증식 효능이 있는 것으로 사료된다.Fig. 2 shows the cell proliferation efficacy results by the concentration ratio of Alcalase hydrolyzate and red ginseng extract of hippocampus. As a result, the cell proliferation efficiency was highest at 200 and 250 ㎍ / ml when the ratio of the hyaline Alcalase hydrolyzate and the red ginseng extract was 0% and 20%, respectively. As a result, the hippocampal Alcalase hydrolyzate itself exhibited cell proliferation It seems to be effective.
그러나 상기에 기재한 바와 같이, 국내에서는 해마를 식품으로 사용하기 위해서는 해마추출물의 함유량을 50% 미만으로 사용해야 하기 때문에 해마 Alcalase 가수분해물과 홍삼 추출물 배합 비율 60%(홍삼추출물 60%, 해마가수분해추출물 40%), 80%(홍삼추출물 80%, 해마가수분해추출물 20%) 일 때의 결과를 살펴보면, 배합 비율이 60%, 80% 일 때 농도 의존적으로 세포 증식 효능이 증가함을 확인할 수 있었다. However, as described above, in order to use hippocampus as a food in domestic, it is necessary to use less than 50% of hippocampus extract. Therefore, the ratio of hydrolyzate of hippocampal Alcalase hydrolyzate and red ginseng extract is 60% (60% of red ginseng extract, 40%), 80% (
마우스 유래 근아세포의 세포증식 효능은 즉 근세포의 증식이 많아지면 그만큼 근육량이 많아지기 때문에 상기의 해마 Alcalase 가수분해물과 홍삼 추출물 배합 비율 60%, 80%이 피로를 덜 받을 수 있다는 것을 간접적으로 보여주는 것으로 사료된다.
The cell proliferation efficiency of mouse derived myoblasts is indirectly shown by the fact that when the proliferation of muscle cells is increased, the amount of muscle mass is increased, so that the mixture ratio of Alcalase hydrolyzate and red ginseng extract of 60% and 80% .
2.2 피로개선 활성 2.2 Fatigue improving activity
마우스 유래 근아세포인 C2C12 세포주를 10% 소혈청(bovine serum)과 L-글루타민을 포함하는 DMEM (Dulbeccos’modified Eagle’medium) 배지를 이용하여 37℃, 5% CO2 배양기에서 배양하였다. 48 well plate에 5×104 cells/ml로 분주한 후, 16 시간이 지난 후 10% 말 혈청이 들어간 DMEM 배지로 바꿔주었다. The mouse-derived myoblast C2C12 cell line was cultured in DMEM (Dulbeccos'modified Eagle'medium) medium containing 10% bovine serum and L-glutamine at 37 ° C in a 5% CO 2 incubator. The cells were divided into 48 well plates at 5 × 10 4 cells / ml, and after 16 hours, they were changed to DMEM containing 10% horse serum.
샘플은 해마 Alcalase 가수분해물과 홍삼 추출물 배합비율(홍삼배합비율 기준으로 0%, 20%, 40%, 60%, 80%, 100%) 농도별로 (200, 250, 300, 400, 500 ㎍/ml처리하였고 총 4일간 배양하였다. (200, 250, 300, 400, 500 ㎍ / ml) of the hydrolysates of Alcalase hydrolyzate and red ginseng extract (0%, 20%, 40%, 60%, 80% And cultured for a total of 4 days.
4일간 배양하는 동안 2일에 한 번씩 배지를 새로 바꿔주고, 샘플도 다시 처리하였다. 4일간 배양 후 배지와 샘플을 바꿔준 후 1시간 후에 피로유도 물질로 100μM H2O2를 세포에 처리 후 24시간 후에 피로개선 활성을 측정하기 위하여 MTT assay를 이용하여 실험하였다. During the 4-day incubation, the medium was replaced once every two days and the samples were again treated. After 4 days of incubation, the media and samples were changed. After 1 hour, the cells were treated with 100 μM H 2 O 2 as a fatigue inducing substance and MTT assay was performed to measure fatigue improving activity 24 hours later.
도 3은 해마 Alcalase 가수분해물과 홍삼 추출물의 배합비율 농도별 피로개선 효능 결과를 나타낸다. 상기 실험 결과 해마 Alcalase 가수분해물과 홍삼 추출물의 배합비율이 60%, 80% 일때 농도 의존적으로 홍삼 100% 보다 피로개선 효능이 더 우수함을 확인할 수 있었고 특히 500 ㎍/ml의 농도일 때 홍삼 100% 샘플과의 확연한 활성차이가 있음을 확인하였다. 이와 같은 결과로 해마 Alcalase 가수분해물과 홍삼 추출물의 배합으로 인해 피로개선 활성에 있어 상승효과가 있음으로 사료된다.
FIG. 3 shows fatigue-improving efficacy results by the concentration ratio of Alcalase hydrolyzate and red ginseng extract. As a result of the above experiment, it was found that the fatigue improving effect was better than that of 100% of red ginseng when the ratio of hyaluronic acid hydrolyzate and red ginseng extract was 60% and 80%, respectively. And a significant difference in activity was observed between the two groups. These results suggest that the combination of hyaline Alcalase hydrolyzate and red ginseng extract has a synergistic effect on fatigue improving activity.
2.3 2.3 InIn vivovivo 모델에서의 피로개선 활성 평가 Evaluation of fatigue improvement activity in model
In vivo 모델로 Zebrafish를 사용하였으며, zebrafish는 인간과 유전적 상동성이 유사한 척추동물로서 손쉽게 이용하기가 쉬워 실험에 사용하였다. 도 4는 In vivo 모델에서의 피로개선 활성측정을 위한 운동 수조를 나타낸다. 상기 운동수조에 Zebrafish 50마리를 각각 해마 Alcalase 가수분해물과 홍삼 추출물의 배합비율별 (Control, 0%, 60%, 80%, 100%)로 그룹을 나누어 2일에 한번 운동, 3일에 한번 샘플 (500 ㎍/ml)을 투여하여 실험하였다. Zebrafish was used as an in vivo model, and zebrafish was vertebrae of similar genetic homology to humans. Figure 4 shows a running water bath for measuring fatigue improving activity in an in vivo model. Fifty animals of Zebrafish were divided into groups according to the mixing ratio of Alcalase hydrolyzate and red ginseng extract (Control, 0%, 60%, 80%, 100% (500 / / ml).
Control 그룹은 해마 Alcalase 가수분해물 및 홍삼 추출물을 먹이지 않은 그룹이다. 운동수조의 유속은 0.3~0.4 m2/sec 이며, zone 1과 2로 나누어 2일에 한번 운동을 시킬 때마다 30분 동안 EthoVision®system을 이용하여 zebrafish가 어느 zone에 더 많이 머물고 이동하는지 유영분석을 하여 실험 결과값을 얻었으며, 실험 시작 후 8일째 되는 날 zebrafish의 근육조직을 얻어 분석하였다. 분석인자들로는 근육내 glycogen 및 ATP 함량과 lactate 함량을 분석하였다. Control group is a group that does not feed Alcalase hydrolyzate and red ginseng extract. The flow rate of the aquarium is 0.3 to 0.4 m 2 / sec. When divided into
도 5는 In vivo 모델인 Zebrafish의 EthoVision®system을 이용한 유영분석 결과를 나타낸다. 상기 실험 결과, (A)의 결과는 Zone 1과 2에 zebrafish가 이동한 횟수를 나타낸 결과로 운동수조를 살펴보면 물 흐름이 Zone 1에서 2로 이동하는 것을 볼 수 있는데, Zone 1에 많이 머무를수록 물살을 거스르는 것이기 때문에 피로개선 효능이 있음을 확인할 수 있다. Figure 5 shows the results of a swimming analysis using the EthoVision system of Zebrafish, an in vivo model. As a result of the experiment, the result of (A) shows the number of zebrafish movements in
해마 Alcalase 가수분해물과 홍삼 추출물의 배합비율이 60%, 80% 일때 0%와 100% 비율보다 zone 1에서 머무는 빈도 수가 증가하고 zone 2에 머무는 빈도 수가 감소함을 확인할 수 있었다. (B)의 결과는 zebrafish가 각각의 zone에 머무는 시간을 분석한 결과로 (A)의 결과와 마찬가지의 패턴을 나타내었다. The frequency of staying in
도 6은 In vivo 모델인 zebrafish 근육 내 glycogen 함량을 나타낸다. zebrafish 내 근육에 존재하는 glycogen 함량을 분석하였한 결과, 해마 Alcalase 가수분해물과 홍삼 추출물의 배합비율이 60%, 80% 일때 0%와 100% 비율보다 glycogen 함량이 더 많음을 알 수 있었다. Figure 6 shows the glycogen content in the in vivo model zebrafish muscle. Analysis of glycogen content in the muscles of zebrafish revealed that glycogen content was higher than that of 0% and 100% when the ratio of hydrolysates of Alcalase hydrolyzate and red ginseng was 60% and 80%, respectively.
이는 glycogen 함량이 높을수록 근육 내 존재하는 에너지가 많음을 알 수 있는 결과로, Alcalase 가수분해물과 홍삼 추출물의 배합비율이 60%, 80% 일때 피로를 덜 느끼는 것으로 사료된다.These results suggest that the higher the glycogen content, the more energy is present in the muscle. Therefore, it is considered that fatigue is less when the ratio of Alcalase hydrolyzate and red ginseng extract is 60% and 80%.
도 7은 In vivo 모델인 zebrafish 근육내 L-Lactate 함량을 나타낸다. 상기 실험 결과, zebrafish 내 근육에 존재하는 L-Lactate 함량을 분석하였다. L-Lactate는 세포 내 생성 및 축적하게 되면 피로를 유발하는 물질로 피로개선 활성측정에 있어 아주 중요한 인자 중에 하나이다. Fig. 7 shows the content of L-lactate in the in vivo model zebrafish muscle. As a result of the above experiment, the content of L-lactate present in the muscle of zebrafish was analyzed. L-lactate is one of the most important factors in the measurement of fatigue-improving activity as it induces fatigue when intracellular production and accumulation occurs.
해마 Alcalase 가수분해물과 홍삼 추출물의 배합비율이 80% 일때 0%와 100% 비율보다 L-Lactate 함량이 현저히 적게 생성되어 피로개선 활성이 있는 것으로 사료된다.L-lactate content was significantly lower than that of 0% and 100% when the ratio of Alcalase hydrolyzate and red ginseng extract was 80%.
도 8은 In vivo 모델인 zebrafish 근육내 ATP 함량을 나타낸다. 상기 실험 결과, zebrafish 내 근육에 존재하는 ATP 함량을 분석한 결과이다. 일반적으로 세포들이 적절한 에너지 공급을 위하여 산소요구량이 급격히 증가하게 되는데 이때 세포들의 대사가 원활히 진행되게 되면 lactate 생성이 없고 ATP 생성이 증가하게 된다. Figure 8 shows the ATP content in the zebrafish muscle, an in vivo model. As a result of the above experiment, the result of analyzing the ATP content in the muscle in zebrafish. In general, when the cells are metabolized smoothly, the production of lactate is increased and the production of ATP is increased.
상기의 결과는 해마 Alcalase 가수분해물과 홍삼 추출물의 배합비율이 80% 일때 0%와 100% 비율보다 ATP 함량이 더 높아 피로누적이 되지 않음을 보여주는 결과이다.
These results show that when the compounding ratio of Alcalase hydrolyzate and red ginseng extract is 80%, the ATP content is higher than 0% and 100%, and the fatigue accumulation is not observed.
완전 양식이 성공된 빅벨리해마와 피로개선의 효능이 알려진 홍삼 추출물을 함유하는 기능성 식품을 제공함으로써, 수산양식산업 뿐만 아니라 기능성 제품 개발 산업을 발전시키고 소득증대의 효과가 있으므로 산업상 이용가능성이 있다.By providing the functional food containing the Big Bell hippocampus and the red ginseng extract, which are known to be effective in improving the fatigue, the functional food product development industry as well as the aquaculture industry can be developed and the effect of the income increase can be industrially applicable .
Claims (4)
Hippocampus abdominalis ) health-functional food composition for improving fatigue containing a mixture of hydrolyzate and red ginseng extract
[Claim 2] The method according to claim 1, wherein the hippocampus and red ginseng extract are mixed at a weight ratio of 1: 1.5-4 and the hippocampus hydrolysis extract is less than 50 wt% Health functional food composition for improving fatigue
3. The fatigue-improving health functional food composition according to claim 2, wherein the concentration of the mixture is 200 to 500 占 퐂 / ml, wherein the composition contains a mixture of hydrolysates of hippocampus and red ginseng extract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160143978A KR101888756B1 (en) | 2016-10-31 | 2016-10-31 | FOOD COMPOSITION CONTAINING HYDROLYSATE DERIVED FROM Hippocampus abdominalis AND EXTRACT OF RED GINSENG FOR RELIEVING FATIGUE |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160143978A KR101888756B1 (en) | 2016-10-31 | 2016-10-31 | FOOD COMPOSITION CONTAINING HYDROLYSATE DERIVED FROM Hippocampus abdominalis AND EXTRACT OF RED GINSENG FOR RELIEVING FATIGUE |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180047602A true KR20180047602A (en) | 2018-05-10 |
KR101888756B1 KR101888756B1 (en) | 2018-09-04 |
Family
ID=62185034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160143978A KR101888756B1 (en) | 2016-10-31 | 2016-10-31 | FOOD COMPOSITION CONTAINING HYDROLYSATE DERIVED FROM Hippocampus abdominalis AND EXTRACT OF RED GINSENG FOR RELIEVING FATIGUE |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101888756B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200101114A (en) | 2019-02-19 | 2020-08-27 | 정읍시 | Food composition comprising Chrysanthemum zawadskii var extract |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030041370A (en) | 2001-11-19 | 2003-05-27 | 이경진 | A composition for treating a sexual dysfunction |
KR20090094072A (en) | 2006-12-12 | 2009-09-03 | 포르슝스첸트룸 칼스루에 게엠베하 | Ball switch in a multiball switch arrangement |
KR101315319B1 (en) * | 2006-11-21 | 2013-10-07 | (주)아모레퍼시픽 | Food composition for fatigue recovery containing extract of ginseng steamed red and Curcuma longa L. |
KR20140042148A (en) | 2012-09-28 | 2014-04-07 | 부경대학교 산학협력단 | Composition for prevention or treatment of neurodegenerative disease comprising bioactive peptide |
KR101596728B1 (en) | 2015-08-11 | 2016-03-07 | 김현성 | Composition comprising zinc/red ginseng, octacosanol and vitamin for preventing and ameliorating andropause symptoms |
-
2016
- 2016-10-31 KR KR1020160143978A patent/KR101888756B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030041370A (en) | 2001-11-19 | 2003-05-27 | 이경진 | A composition for treating a sexual dysfunction |
KR101315319B1 (en) * | 2006-11-21 | 2013-10-07 | (주)아모레퍼시픽 | Food composition for fatigue recovery containing extract of ginseng steamed red and Curcuma longa L. |
KR20090094072A (en) | 2006-12-12 | 2009-09-03 | 포르슝스첸트룸 칼스루에 게엠베하 | Ball switch in a multiball switch arrangement |
KR20140042148A (en) | 2012-09-28 | 2014-04-07 | 부경대학교 산학협력단 | Composition for prevention or treatment of neurodegenerative disease comprising bioactive peptide |
KR101596728B1 (en) | 2015-08-11 | 2016-03-07 | 김현성 | Composition comprising zinc/red ginseng, octacosanol and vitamin for preventing and ameliorating andropause symptoms |
Non-Patent Citations (1)
Title |
---|
그러나 상기 선행문헌은 본 발명의 해마 가수분해물과 홍삼 추출물의 혼합물을 함유하는 피로개선용 건강 기능성 식품 조성물과 관련된 구성은 개시되지 않아 차이를 보인다. |
Also Published As
Publication number | Publication date |
---|---|
KR101888756B1 (en) | 2018-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ji et al. | Antioxidant and anti-inflammatory activity of peptides from foxtail millet (Setaria italica) prolamins in HaCaT cells and RAW264. 7 murine macrophages | |
TWI659746B (en) | Composition containing collagen peptide, elastin peptide, and proteoglycan | |
Xiao et al. | Anti-fatigue property of the oyster polypeptide fraction and its effect on gut microbiota in mice | |
JP2011511620A (en) | Amino acid and peptide products | |
US20160074457A1 (en) | Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome | |
He et al. | Nutritional and medicinal characteristics of Chinese giant salamander (Andrias davidianus) for applications in healthcare industry by artificial cultivation: a review | |
KR20190072617A (en) | Compositions of fish skin collagen peptides and their use as medicaments | |
KR20110005294A (en) | Glutathione production enhancer, prophylactic/therapeutic agent for diseases associated with lack of glutachione, and food, beverage and feed | |
CN107427547A (en) | Water-soluble mussel extract | |
Mehram et al. | Potential effects of food processing byproducts on neurological and immunological disorders of obese rats | |
KR101888756B1 (en) | FOOD COMPOSITION CONTAINING HYDROLYSATE DERIVED FROM Hippocampus abdominalis AND EXTRACT OF RED GINSENG FOR RELIEVING FATIGUE | |
KR102478759B1 (en) | Peptides for liver protection, hangover relief, antioxidant and anti-inflammation | |
KR102158667B1 (en) | Pediococcus inopinatus WiKim0108 strain controlling immune function and ameliorating inflammatory bowel disease and use thereof | |
Wang et al. | Structural properties, anti-fatigue and immunological effect of low molecular weight peptide from Monkfish | |
CN101284061B (en) | Chinese herbal medicine formulations for promoting the yellow catfish growing | |
KR101809800B1 (en) | A pharmaceutical composition comprising anti-allergic peptide isolated from abalone intestine | |
RU2567053C2 (en) | Composition, accelerating adiponectin production | |
KR102255499B1 (en) | Novel antioxidant peptides and pharmaceutical composition for preventing or treating cardiovascular disease | |
JP5684989B2 (en) | Enzyme-treated and gonococcal fermentation-treated product | |
KR102312675B1 (en) | A composition for improving, preventing and treating of anti-inflammatory, obesity and nonalcoholic fatty liver disease comprising Artemisia Annua extract, Magnolia Obovata Bark extract and its mixed extracts | |
JP6944240B2 (en) | An agent for maintaining or increasing the content of fibrous structural proteins in living tissues containing GABA as an active ingredient. | |
CN116114871B (en) | Chinese health-preserving composition for enhancing immunity and preparation method and application thereof | |
KR102008621B1 (en) | Composition for Increas of Muscle Growth or Improvement of Exercise Performance Using Fractions of Alcalase Hydrolysates of Hippocampus abdominalis, or Effective Peptides Thereof | |
TW201713357A (en) | Anti-obesity composition | |
Mahmoud et al. | Egyptian “Ful Medames” Mitigates Metabolic Syndrome-Associated Inflammation through Regulation of Resistin, Leptin and Adipokine mRNA Expression in Wistar Rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
R401 | Registration of restoration |